KR20130137635A - 암의 진단을 위한 골수 세포 생체지표의 용도 - Google Patents

암의 진단을 위한 골수 세포 생체지표의 용도 Download PDF

Info

Publication number
KR20130137635A
KR20130137635A KR1020137010009A KR20137010009A KR20130137635A KR 20130137635 A KR20130137635 A KR 20130137635A KR 1020137010009 A KR1020137010009 A KR 1020137010009A KR 20137010009 A KR20137010009 A KR 20137010009A KR 20130137635 A KR20130137635 A KR 20130137635A
Authority
KR
South Korea
Prior art keywords
cancer
patient
mdsc
treatment
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020137010009A
Other languages
English (en)
Korean (ko)
Inventor
하프리트 싱
스테펜 발터
레지나 멘드르지크
빈센조 브론테
수산나 만드루짜토
Original Assignee
이매틱스 바이오테크놀로지스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이매틱스 바이오테크놀로지스 게엠베하 filed Critical 이매틱스 바이오테크놀로지스 게엠베하
Publication of KR20130137635A publication Critical patent/KR20130137635A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
KR1020137010009A 2010-09-21 2011-09-21 암의 진단을 위한 골수 세포 생체지표의 용도 Withdrawn KR20130137635A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38478410P 2010-09-21 2010-09-21
GBGB1015765.9A GB201015765D0 (en) 2010-09-21 2010-09-21 Use of myeloid cell biomarkers for the diagnosis of cancer
US61/384,784 2010-09-21
GB1015765.9 2010-09-21
PCT/EP2011/066397 WO2012038463A2 (en) 2010-09-21 2011-09-21 Use of myeloid cell biomarkers for the diagnosis of cancer

Publications (1)

Publication Number Publication Date
KR20130137635A true KR20130137635A (ko) 2013-12-17

Family

ID=43065538

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137010009A Withdrawn KR20130137635A (ko) 2010-09-21 2011-09-21 암의 진단을 위한 골수 세포 생체지표의 용도

Country Status (10)

Country Link
US (1) US9671404B2 (https=)
EP (1) EP2619585B1 (https=)
JP (1) JP5970459B2 (https=)
KR (1) KR20130137635A (https=)
CN (1) CN103180739B (https=)
CA (1) CA2811070A1 (https=)
EA (1) EA201390413A1 (https=)
GB (1) GB201015765D0 (https=)
SG (2) SG188543A1 (https=)
WO (1) WO2012038463A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190082094A (ko) * 2017-12-29 2019-07-09 연세대학교 산학협력단 면역 항암 요법에 대한 치료 반응 예측 방법
KR20190088403A (ko) * 2017-06-02 2019-07-26 이종균 대장 직장암 환자와 정상인의 말초혈액 내 면역세포의 분포 차이를 이용하여 면역력을 평가하고 암 발병 유무에 대한 정보를 제공하는 방법 및 이를 이용한 진단키트

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
EP3682896A1 (en) * 2011-04-28 2020-07-22 University of Southern California Human myeloid derived suppressor cell cancer markers
WO2013169913A1 (en) 2012-05-08 2013-11-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Predictors of patient response to interferon-a therapy
WO2014159923A1 (en) * 2013-03-13 2014-10-02 Health Research, Inc. Enhancement of vaccines
CN103743907B (zh) * 2013-07-24 2015-04-15 北京大学人民医院 测定造血干细胞移植后患者骨髓微循环环境评测的试剂盒、系统及方法
WO2015048748A1 (en) * 2013-09-30 2015-04-02 Board Of Regents, The University Of Texas System Myeloid-derived suppressor cell-specific peptides for diagnostic and therapeutic use
CN103626846B (zh) * 2013-11-08 2016-06-01 上海交通大学 与MDSCs特异性结合的配体多肽及药物输送系统
EP3012271A1 (en) * 2014-10-24 2016-04-27 Effimune Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
CA2990852A1 (en) * 2015-06-26 2016-12-29 Beth Israel Deaconess Medical Center, Inc. Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
AU2016318136B2 (en) 2015-09-02 2022-10-20 Syndax Pharmaceuticals, Inc. Selection of patients for combination therapy
RU2729116C2 (ru) 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
GB201604490D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
RS66062B1 (sr) 2016-04-14 2024-11-29 Ose Immunotherapeutics Nova anti-sirpa antitela i njihove terapijske primene
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
CN107102127B (zh) * 2017-04-07 2019-08-06 东北师范大学 一种人体外周血中单核样髓源抑制细胞的检测方法
WO2018213665A1 (en) 2017-05-19 2018-11-22 Syndax Pharmaceuticals, Inc. Combination therapies
KR20260039788A (ko) 2017-10-10 2026-03-20 시애틀 프로젝트 코포레이션 핫스팟을 이용한 신생항원 동정
JP7395471B2 (ja) 2017-10-13 2023-12-11 オーセ イミュノセラピューティクス 改変抗ＳＩＲＰａ抗体及びその使用
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
AU2019233577A1 (en) 2018-03-13 2020-09-03 Ose Immunotherapeutics Use of anti-human SIRPa v1 antibodies and method for producing anti-SIRPa v1 antibodies
AU2019266231B2 (en) 2018-05-07 2025-08-21 Syndax Pharmaceuticals, Inc. Selection of patients for combination therapy
CN110501483B (zh) * 2019-07-25 2020-12-29 同济大学 一种中草药活性的检测方法
TR202003833A1 (tr) 2020-03-12 2021-09-21 Hacettepe Ueniversitesi Rektoerluek Mi̇yeloi̇d kökenli̇ baskilayici hücrelere özgü bi̇yobeli̇rteç paneli̇
BR112023025194A2 (pt) 2021-06-04 2024-02-27 Boehringer Ingelheim Int Anticorpos anti-sirp-alfa
CN117054649A (zh) * 2023-08-04 2023-11-14 广州中医药大学第一附属医院 一种慢性萎缩性胃炎向胃癌转化标志物及其应用
CN117030580B (zh) * 2023-09-15 2024-07-16 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） LDNs在坏死性小肠结肠炎诊断中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US20040136973A1 (en) * 2002-11-07 2004-07-15 Eliezer Huberman Human stem cell materials and methods
US8329408B2 (en) * 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
GB0820698D0 (en) * 2008-11-12 2008-12-17 Ludwig Inst Cancer Res Uses of immunomodulators

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190088403A (ko) * 2017-06-02 2019-07-26 이종균 대장 직장암 환자와 정상인의 말초혈액 내 면역세포의 분포 차이를 이용하여 면역력을 평가하고 암 발병 유무에 대한 정보를 제공하는 방법 및 이를 이용한 진단키트
KR20190082094A (ko) * 2017-12-29 2019-07-09 연세대학교 산학협력단 면역 항암 요법에 대한 치료 반응 예측 방법

Also Published As

Publication number Publication date
US9671404B2 (en) 2017-06-06
EP2619585A2 (en) 2013-07-31
WO2012038463A2 (en) 2012-03-29
GB201015765D0 (en) 2010-10-27
JP5970459B2 (ja) 2016-08-17
WO2012038463A3 (en) 2012-07-26
CN103180739B (zh) 2016-08-03
EP2619585B1 (en) 2017-03-01
SG10201510470WA (en) 2016-01-28
US20120070461A1 (en) 2012-03-22
JP2013539857A (ja) 2013-10-28
EA201390413A1 (ru) 2013-07-30
CN103180739A (zh) 2013-06-26
SG188543A1 (en) 2013-04-30
CA2811070A1 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
KR20130137635A (ko) 암의 진단을 위한 골수 세포 생체지표의 용도
Wu et al. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia
Tessari et al. Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?
US20210017607A1 (en) Methods of Predicting Responsiveness to Cancer Therapies
Wang et al. CD103+ CD8+ T lymphocytes in non-small cell lung cancer are phenotypically and functionally primed to respond to PD-1 blockade
EP3022561A1 (en) Method for the prognosis of survival time of a patient suffering from a solid cancer
Heng et al. High expression of tumor HLA-DR predicts better prognosis and response to anti-PD-1 therapy in laryngeal squamous cell carcinoma
Yu et al. Aberrant expression and association of VEGF and Dll4/Notch pathway molecules under hypoxia in patients with lung cancer
JP7216420B2 (ja) がん治療効果の検査方法及び免疫応答誘導用組成物
Yu et al. CCR9-CCL25 mediated plasmacytoid dendritic cell homing and contributed the immunosuppressive microenvironment in gastric cancer
Lu et al. Basic transcription factor 3 like 4 enhances malignant phenotypes through modulating tumor cell function and immune microenvironment in glioma
JP2024151758A (ja) 肝臓癌を治療する方法、治療に対する応答を予測する方法、及び肝臓癌の治療中の有害作用を予測する方法
JP7255896B2 (ja) シクロホスファミド療法に対する応答者の予測
Schmitt et al. The tumor antigens RHAMM and G250/CAIX are expressed in head and neck squamous cell carcinomas and elicit specific CD8+ T cell responses
WO2023218399A1 (en) Method of preparing and expanding a population of immune cells for cancer therapy, potency assay for tumor recognition, biological vaccine preparation and epitope target for antibodies
KR20230062834A (ko) 암 치료에 대한 반응을 예측하기 위한 바이오마커
Pourmir Membrane and soluble forms of the immune checkpoint TIM-3 in clear cell renal cell carcinoma: a promising biomarker for cancer immunotherapy
HK1183096A (en) Use of myeloid cell biomarkers for the diagnosis of cancer
HK1183096B (en) Use of myeloid cell biomarkers for the diagnosis of cancer
Navarrete-Sirvent Nk cells as biomarkers of response to antiegfr therapy in metastatic colorectal cancer: clinical implications and therapeutic opportunities
Sam CD27-CD70 interaction: novel predictive biomarker of immunotherapy in renal cell carcinoma and melanoma
US20240307516A1 (en) Combination therapy for cancer
Camcı et al. Prognostic significance of Wilms Tumor 1 (WT1) protein expression in breast cancer
JP7042753B2 (ja) 免疫チェックポイント阻害剤の投与対象となる個体の選択方法
Kostine Defining the immune microenvironment in sarcoma: could immunotherapy be part of the treatment strategy in sarcoma patients?

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202

WITB Written withdrawal of application
P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000